Medicinal kit to quit tobacco consumption comprising central cannabinoid receptor antagonist

Abstract

The invention relates to the use of a medicinal kit comprising N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide for helping to quit tobacco consumption.

1 . A kit for helping to quit tobacco consumption, containing N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide, a pharmaceutically acceptable salt thereof or a solvate thereof and another active principle for helping to quit tobacco consumption, in which the N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide, a pharmaceutically acceptable salt thereof, a solvate thereof and the said active principle are in separate compartments and in packaging which may be identical or different and are intended to be administered simultaneously, separately or sequentially.  
     
     
         2 . The kit as claimed in  claim 1 , containing N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide, a pharmaceutically acceptable salt thereof or a solvate thereof and nicotine, a nicotine agonist or a partial nicotine agonist.  
     
     
         3 . The kit as claimed in  claim 1 , containing N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide, a pharmaceutically acceptable salt thereof or a solvate thereof and a monoamine oxidase inhibitor.